{"title":"新型冠状病毒感染(COVID - 19)导致的难治性大量腹泻一例(A case of refractory massive diarrhea in A patient with)covid - 19)","authors":"清水 健太郎 (Kentaro Shimizu), 平田 陽彦 (Haruhiko Hirata), 德平 夏子 (Natsuko Tokuhira), 上田 安希子 (Akiko Ueda), 元岡 大祐 (Daisuke Motooka), 中村 昇太 (Shota Nakamura), 小倉 裕司 (Hiroshi Ogura)","doi":"10.1002/jja2.12653","DOIUrl":null,"url":null,"abstract":"ABSTRACT The new coronavirus disease (COVID–19) causes gastrointestinal symptoms as well as respiratory symptoms. We report a case of massive refractory diarrhea from the perspective of gut microbiota. A 60–year–old man was transferred with dyspnea. He was diagnosed as having COVID–19 and was intubated on mechanical ventilation with extracorporeal membrane oxygenation. He was administered anti–viral drug therapy and antibiotics. He suffered from diarrhea from day 12 and produced a maximum of about 6,384mL/day of watery diarrhea on day 21. He required massive transfusion and catecholamines for circulatory support. Adsorbents, pectin–containing oligomeric formulas and synbiotics were administered, which decreased the amounts of diarrhea. After day 30, the amount of diarrhea decreased to less than 1,000mL/day. Fecal metagenomic analysis showed the proportions of Enterococcus and Staphylococcus in the phylum Firmicutes were the most dominate at the genus level. The proportion of Bacteroidetes was less than 1%, and the gut microbiota had dramatically changed. Thereafter, his diarrhea decreased to occasional instances, and he was transferred to another ward on day 104. Therapy for intestinal complications might be important in treating COVID–19. Intestinal therapy such as adsorbents might be effective in patients with massive diarrhea.","PeriodicalId":200165,"journal":{"name":"Nihon Kyukyu Igakkai Zasshi","volume":"142 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"新型コロナウイルス感染症(COVID–19)に伴う難治性大量下痢症の1例(A case of refractory massive diarrhea in a patient with COVID–19)\",\"authors\":\"清水 健太郎 (Kentaro Shimizu), 平田 陽彦 (Haruhiko Hirata), 德平 夏子 (Natsuko Tokuhira), 上田 安希子 (Akiko Ueda), 元岡 大祐 (Daisuke Motooka), 中村 昇太 (Shota Nakamura), 小倉 裕司 (Hiroshi Ogura)\",\"doi\":\"10.1002/jja2.12653\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ABSTRACT The new coronavirus disease (COVID–19) causes gastrointestinal symptoms as well as respiratory symptoms. We report a case of massive refractory diarrhea from the perspective of gut microbiota. A 60–year–old man was transferred with dyspnea. He was diagnosed as having COVID–19 and was intubated on mechanical ventilation with extracorporeal membrane oxygenation. He was administered anti–viral drug therapy and antibiotics. He suffered from diarrhea from day 12 and produced a maximum of about 6,384mL/day of watery diarrhea on day 21. He required massive transfusion and catecholamines for circulatory support. Adsorbents, pectin–containing oligomeric formulas and synbiotics were administered, which decreased the amounts of diarrhea. After day 30, the amount of diarrhea decreased to less than 1,000mL/day. Fecal metagenomic analysis showed the proportions of Enterococcus and Staphylococcus in the phylum Firmicutes were the most dominate at the genus level. The proportion of Bacteroidetes was less than 1%, and the gut microbiota had dramatically changed. Thereafter, his diarrhea decreased to occasional instances, and he was transferred to another ward on day 104. Therapy for intestinal complications might be important in treating COVID–19. Intestinal therapy such as adsorbents might be effective in patients with massive diarrhea.\",\"PeriodicalId\":200165,\"journal\":{\"name\":\"Nihon Kyukyu Igakkai Zasshi\",\"volume\":\"142 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nihon Kyukyu Igakkai Zasshi\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/jja2.12653\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nihon Kyukyu Igakkai Zasshi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/jja2.12653","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
新型冠状病毒病(COVID-19)除了引起呼吸道症状外,还会引起胃肠道症状。我们从肠道菌群的角度报告一例大量难治性腹泻。一名60岁男性因呼吸困难转诊。他被诊断为COVID-19,并插管机械通气体外膜氧合。他接受了抗病毒药物治疗和抗生素治疗。他从第12天开始腹泻,并在第21天最多产生约6384 ml /天的水样腹泻。他需要大量输血和儿茶酚胺来维持血液循环。吸附剂、含果胶的低聚物制剂和合成制剂均可减少腹泻量。第30天,腹泻量减少至小于1000ml /天。粪便宏基因组分析显示,厚壁菌门中肠球菌和葡萄球菌的比例在属水平上最占优势。拟杆菌门所占比例不到1%,肠道菌群发生了巨大变化。此后腹泻减少为偶发,第104天转至另一病房。肠道并发症的治疗可能对治疗COVID-19很重要。肠道治疗如吸附剂可能对大量腹泻患者有效。
新型コロナウイルス感染症(COVID–19)に伴う難治性大量下痢症の1例(A case of refractory massive diarrhea in a patient with COVID–19)
ABSTRACT The new coronavirus disease (COVID–19) causes gastrointestinal symptoms as well as respiratory symptoms. We report a case of massive refractory diarrhea from the perspective of gut microbiota. A 60–year–old man was transferred with dyspnea. He was diagnosed as having COVID–19 and was intubated on mechanical ventilation with extracorporeal membrane oxygenation. He was administered anti–viral drug therapy and antibiotics. He suffered from diarrhea from day 12 and produced a maximum of about 6,384mL/day of watery diarrhea on day 21. He required massive transfusion and catecholamines for circulatory support. Adsorbents, pectin–containing oligomeric formulas and synbiotics were administered, which decreased the amounts of diarrhea. After day 30, the amount of diarrhea decreased to less than 1,000mL/day. Fecal metagenomic analysis showed the proportions of Enterococcus and Staphylococcus in the phylum Firmicutes were the most dominate at the genus level. The proportion of Bacteroidetes was less than 1%, and the gut microbiota had dramatically changed. Thereafter, his diarrhea decreased to occasional instances, and he was transferred to another ward on day 104. Therapy for intestinal complications might be important in treating COVID–19. Intestinal therapy such as adsorbents might be effective in patients with massive diarrhea.